Compare Stocks → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:EMHNASDAQ:PMNNASDAQ:RENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsPMNProMIS Neurosciences$1.91+9.1%$2.01$0.95▼$8.95$36.08M0.6818,186 shs9,199 shsRENECartesian Growth Co. II$11.11-0.1%$11.06$10.47▼$11.92$240.20M-0.0138,638 shs11,219 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%PMNProMIS Neurosciences+9.14%-0.07%-7.73%+66.09%-60.04%RENECartesian Growth Co. II-0.09%+0.09%+0.45%+1.55%+6.11%Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the detailsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences2.3456 of 5 stars3.53.00.00.02.41.70.6RENECartesian Growth Co. IIN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMHEmerald Health TherapeuticsN/AN/AN/AN/APMNProMIS Neurosciences3.00Buy$8.00318.85% UpsideRENECartesian Growth Co. IIN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64PMNProMIS Neurosciences$10K3,607.99N/AN/A($0.16) per share-11.94RENECartesian Growth Co. IIN/AN/A$0.40 per share27.94($0.64) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/APMNProMIS Neurosciences-$18.06M-$1.94N/AN/AN/AN/AN/A-219.98%4/3/2024 (Estimated)RENECartesian Growth Co. II$11.44MN/A0.00∞N/AN/A-65.59%5.02%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ARENECartesian Growth Co. IIN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMHEmerald Health Therapeutics35.452.972.61PMNProMIS NeurosciencesN/A1.811.81RENECartesian Growth Co. IIN/A0.220.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMHEmerald Health TherapeuticsN/APMNProMIS Neurosciences50.13%RENECartesian Growth Co. II58.96%Insider OwnershipCompanyInsider OwnershipEMHEmerald Health TherapeuticsN/APMNProMIS Neurosciences10.30%RENECartesian Growth Co. II20.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionablePMNProMIS Neurosciences618.89 million16.94 millionNot OptionableRENECartesian Growth Co. IIN/A21.62 million17.30 millionNot OptionableEMH, PMN, and RENE HeadlinesSourceHeadlineCartesian Growth Co. II (NASDAQ:RENE) Short Interest Updatemarketbeat.com - March 28 at 8:23 PMShort Interest in Cartesian Growth Co. II (NASDAQ:RENE) Declines By 94.0%marketbeat.com - March 12 at 11:33 PMCartesian Growth Co. II (NASDAQ:RENE) Sees Large Drop in Short Interestmarketbeat.com - March 1 at 10:37 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEmerald Health TherapeuticsCVE:EMHEmerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Cartesian Growth Co. IINASDAQ:RENECartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.